Mabion SA – Polish, biopharmaceutical Company dedicated to development of therapeutic proteins, mostly monoclonal antibodies will present their achievements during the fair CPhl Worldwide in Paris. The participants of event will have the opportunity to familiarize with the offer of drugs, over whom the company is working – MabionCD20, MabionHER2, MabionVEGF, MabionVEGF-Fab, MabionEGFR – and insulin analogues. In addition Mabion present a wide range of services related to contract manufacture and analytics laboratory. Fair will be held from 7 - 9 October.
The CPhl Worldwide is one of the largest and most important exhibition of pharmaceutical in which key representatives of the industry participate. Brings together over 29,000 participants from over 140 countries. For over 20 years provides an excellent opportunity to initiate cooperation in science and business across Europe and enables the development of partnership firms, investors and scientists.
„We have high hopes for the upcoming CPhl fair, which this year will take place in Paris. Attendance at such events consistently translates into signing new contracts relating to the registration, distribution and sales in foreign markets MabionCD20. Participation in projects such as trade fairs and conferences, gives us the opportunity to find strong partners and counterparties - through which we can carry out sales on non-regulated markets. Moreover, the presence at trade fairs CPhl in Paris - which enjoy popularity among traders on the European and global pharmaceutical industry - provides an excellent opportunity to showcase our achievements” – said Maciej Wieczorek, Mabion SA, President of the Board.
Mabion intends to register MabionCD20 on all global markets where reference drugs are sold. Geographically, it can be divided into three major regions: the United States, European Union countries and other countries of the world, where the registration is less strictly regulated. The company intends to register
MabionCD20 across the European Union on their own after completion of clinical trials in collaboration with dozens of centers in selected European countries.
In the case of regions with a less strictly regulated system of registration - such as Africa or Asia - Mabion SA is planning both implementation of sales and the entire registration process by local leading pharmaceutical companies. Production will be carried out in Mabion’s factories in Poland, and the company will have shares in the revenues from the sale of drugs by foreign distributors. By now Mabion has
• An agreement with the pharmaceutical company LYFIS for the territory of Iceland
• An agreement with the Ukrainian pharmaceutical company Farmak in relation to Ukraine, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan
• An agreement with the Turkish pharmaceutical company ONKO referring to the territory of Turkey • An agreement with Costa Rican pharmaceutical company in relation to the countries of Central America (Costa Rica, Honduras, Nicaragua, Belize, Dominican Republic, El Salvador, Trinidad and Tobago and Panama)
• An agreement with the Moroccan pharmaceutical company Sothema Laboratories for countries of North Africa (Morocco, Algeria and Tunisia)
• An agreement with the Argentine pharmaceutical company LKM SA in relation to South America (Argentina, Colombia, Venezuela, Peru, Chile, Paraguay, Ecuador, Bolivia and Uruguay)
• A letter of intent with a pharmaceutical company from Lebanon in relation to the Middle East
• A letter of intent with a pharmaceutical company from Croatia in relation to the Balkan countries
Company information:
MABION SA is a leading biotechnological Polish company focused on development and implementation of new generation biosimilar drugs based on humanized monoclonal antibodies and therapeutic proteins. Over the past few years Mabion has gained the ability to produce free-form biotechnology drugs starting from the design step, through the selection of a manufacturing platform and technology, to obtaining the final product. The process of humanization of monoclonal antibodies, which is the topmost achievement in the present biotechnology, enables production of targeted drugs that act specifically resulting in better effectiveness and lower toxicity of the therapy. The key goals of Mabion are to provide a wide range of biotechnological drugs (MabionCD20, MabionHER2, MabionVEGF and MabionEGFR), its registration and introduction to the market just as the basic license protection for reference drugs expires (in EU it will happen between 2014 and 2018). The first mAb MabionCD20 is used to treat blood cancer – lymphomas and leukemias as well as rheumatoid arthritis. second mAb MabionHER2 that is used for breast cancer is under process and analytical tools development. Clinical development of two next antibodies – anti VEGF and anti EGFR – is planned in 2012 – 2013.
Mabion SA is the only company located in CEE which developed its own technology platform of recombinant scaled therapeutics production in CEE and has successfully performed the first ever industrial scale (2500 l) recombinant CHO cells cultivation process using bioreactor fully based on disposable technology. It is also one of the most advanced companies with regard to clinical development of top quality biosimilars compliant with standards of the European Medicines Agency (EMA) and U.S. Food and Drugs Administration (FDA). The total value of the worldwide market covered with drugs developed by Mabion is USD 20 billion. The company built experienced team consisting of professors, PhDs, MScs of biotechnology, molecular biology and chemistry who are ready to face every challenge regarding projecting and manufacturing biotechnological drugs, recombinant CHO cells and analog insulin. The company intends to register MabionCD20 on all global markets where reference drugs are sold. Those can be divided geographically into several regions: EU, USA, other highly regulated countries: Japan, Canada, Australia, New Zeland and countries with less advanced regulations regarding biosimilars. Since April 2013 Mabion is listed on the Warsaw Stock Exchange and obtained PLN 61,8 million (approx. EUR 14,64 million) from the Initial Public Offering (IPO) and private issues emissions. The company also obtained nearly PLN 64 million (approx. EUR 15,17 million) from the European Union’s financial support program for innovative projects.
www.mabion.eu
Help employers find you! Check out all the jobs and post your resume.
